Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

capmatinib

Known as: 2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide 
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
9004Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data of GEOMETRY mono-1 study showed a… Expand
Is this relevant?
2019
2019
Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2018
Highly Cited
2018
PURPOSE MET dysregulation occurs in up to 26% of non-small-cell lung cancers (NSCLCs) after epidermal growth factor receptor… Expand
Is this relevant?
Review
2018
Review
2018
Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met… Expand
  • figure 1
  • table 1
Is this relevant?
2018
2018
Purpose Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2017
2017
Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some patients with HCC initially respond to… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients initially benefit from the EGFR-inhibitor… Expand
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2016
2016
9067Background: cMET dysregulation occurs in 3–10% of NSCLC and is a negative prognostic factor. INC280 is a highly selective… Expand
Is this relevant?
2016
2016
9020Background: Most pts withEGFR-mut NSCLC progress on EGFR tyrosine kinase inhibitor (TKI) therapy despite high initial… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Purpose: To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?